Arrowhead price target raised to $80 from $60 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...
Zacks Small Cap Research on MSN19h
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
Muscular Dystrophy News19h
Sarepta to develop Arrowhead’s muscular dystrophy treatments
Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...
What's on Netflix17h
Netflix News
Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...